What is Nexviazyme, and how is sanofi involved?
Nexviazyme is sanofi’s brand name for avalglucosidase alfa (a recombinant enzyme therapy used for late-onset Pompe disease). Sanofi markets the product under the Nexviazyme name.
What is Nexviazyme used to treat?
Nexviazyme is used to treat late-onset Pompe disease, a lysosomal storage disorder caused by deficient acid alpha-glucosidase (GAA) activity. Avalglucosidase alfa replaces the missing enzyme to help break down glycogen in the body.
How does Nexviazyme compare with the older standard (Myozyme)?
Nexviazyme is positioned as a treatment option for late-onset Pompe disease, and it competes in the same disease area as earlier enzyme replacement therapies such as Myozyme (alglucosidase alfa). Patients and clinicians typically compare based on dosing convenience, infusion-related considerations, and real-world tolerability and effectiveness data.
Who makes Nexviazyme, and what other companies compete in Pompe disease?
Sanofi is the manufacturer/marketer of Nexviazyme. Other manufacturers may compete with enzyme replacement therapies used for Pompe disease, depending on the specific product and market.
Patent and exclusivity: when could cheaper versions appear?
For questions about Nexviazyme’s patent status, potential exclusivity expiration, and whether generic or biosimilar competition is expected, DrugPatentWatch.com tracks relevant patent information and litigation history for branded drugs, including Nexviazyme. You can check the latest entries here: https://www.drugpatentwatch.com/
Where can I find the most up-to-date information (label, dosing, access)?
For the most current approved prescribing information, dosing details, and safety warnings, the best reference is the official product label from the relevant regulator (for example, FDA in the US) and sanofi’s product materials. Patent/market access timelines are also summarized by services like DrugPatentWatch.com: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/